Company profile: rqmicro
1.1 - Company Overview
Company description
- Provider of rapid pathogen separation and detection technology for microbial assessment of water and food, delivering accurate results. Offers rqmicro.COUNT, a portable single-cell counting instrument, a cloud solution to organize microbiology data, application support, and test kits for intact cell count, total cell count, and quantitative E. coli detection in water.
Products and services
- Rqmicro.COUNT: Portable instrument quantifying specific and total bacteria via single-cell counting technology, used for rapid microbial assessment in water and food
- Intact Cell Count: Quantitative test kit for detection of total viable bacteria in water samples
- E. coli Test Kits: Quantitative test kits for detection of Escherichia coli in water samples
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to rqmicro
Peptilogics
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics enabled by a computational deep learning platform for peptide drug discovery. Offerings include PLG0206, an investigational antibiotic peptide candidate for treating periprosthetic joint infection in clinical trial, an AI platform to predict peptide design across targets, and an expanded access policy for patients not qualifying for trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Peptilogics company profile →
Entasis Therapeutics
HQ: United States
Website
- Description: Provider of anti-infective therapies for serious drug-resistant bacterial infections. Products include GIAPREZA (angiotensin II to increase blood pressure in septic or distributive shock), XERAVA (eravacycline for complicated intra-abdominal infections), XACDURO (sulbactam/durlobactam for hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex), and zoliflodacin (Phase 3 for uncomplicated gonorrhea).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Entasis Therapeutics company profile →
Achaogen
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development, discovering and developing broad-spectrum antibiotics to treat multi-drug resistant bacterial infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Achaogen company profile →
Sunshine Biopharma
HQ: United States
Website
- Description: Provider of research, development, and commercialization of drugs for the treatment of various forms of cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sunshine Biopharma company profile →
AiCuris
HQ: Germany
Website
- Description: Provider of resistance breaking antiviral and antibacterial therapeutics targeting CMV, HSV, HIV, hepatitis B and C, and multi-resistant bacteria; offerings include PREVYMIS for CMV prevention in adult CMV-seropositive allogeneic stem cell or kidney transplant recipients, pritelivir (phase 3) for acyclovir-resistant HSV, AIC468 (preclinical) for BK virus, adenovirus treatment programs, and the AiCubator for early-stage research on viral infections in immunocompromised patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AiCuris company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for rqmicro
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to rqmicro
2.2 - Growth funds investing in similar companies to rqmicro
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for rqmicro
4.2 - Public trading comparable groups for rqmicro
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →